PGI21 - COST-EFFECTIVENESS ANALYSIS OF USTEKINUMAB VERSUS ADALIMUMAB, INFLIXIMAB AND VEDOLIZUMAB FOR THE TREATMENT OF PATIENTS WITH MODERATELY TO SEVERE ACTIVE CROHN’S DISEASE FOR TURKEY
Abstract
Authors
M. Arhan H.A. Tezel M. Toruner B. Bilaloğlu S. Koral E. Ozer